Aliskiren Effect on Aortic Plaque Progression
Stopped early · Phase 2/Phase 3 · Has a placebo group
Conditions studied: Atherosclerosis
In brief
This study is being done to assess the effectiveness of short term (\~9 months) Aliskiren/Placebo therapy to slow down the progression of atherosclerotic disease in thoracic and abdominal aorta. This will be checked by comparing before and after therapy magnetic resonance imaging (MRI) pictures of the aortic wall. Aliskiren is an FDA approved drug for hypertension but in this study is used for a new indication. Recent studies with animals have shown that Aliskiren therapy reduces the atherosclerotic plaque. Therefore, in this study, the investigators would like to evaluate whether the investigational drug Aliskiren, which is not FDA approved for this indication has the same beneficial effects in people with atherosclerotic disease.
Key facts
- Study ID
- NCT01417104
- Run by
- Ohio State University
- People needed
- 71
- Starts
- 2009-10-01
- Expected to finish
- 2012-01-01
- Last updated by the study team
- 2017-05-11
Who can join
Age: 45 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Ohio State University — Columbus, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.